Seattle, Washington 98108


The purpose of this study is to see if a medication called prazosin is useful in the treatment of agitation and aggression in persons with Alzheimer's disease and other types of dementia in late life.

Study summary:

Although the occurrence of disruptive agitation behaviors likely are influenced by environmental/ interpersonal factors, it is also likely that behaviorally relevant neurobiologic abnormalities lower the threshold for the expression of such behavior in AD. Because of the success prazosin has had in the treatment of PTSD, it is thought that it could be used similarly with disruptive agitation. Originally designed to evaluate AD patients in nursing homes, the study now includes outpatients. It is a 9-week placebo-controlled trial.


Inclusion Criteria: - No age limit - probable/possible AD diagnosis - disruptive agitated behaviors (e.g., irritability, aggression, uncooperativeness, pacing) - no hypotension - no concurrent use of alpha-1-blockers - no delirium, schizophrenia, mania, psychotic symptoms. Exclusion Criteria: - Cardiovascular: unstable angina, recent MI, second or third degree AV block, preexisting hypotension (systolic BP less than 110) or orthostatic hypotension - Other medical exclusions: chronic renal or hepatic failure, or any unstable medical condition - Exclusionary medications: current treatment with prazosin, other alpha-1-blockers - Current enrollment in a separate investigational drug trial - Psychoactive medications: subjects may be psychoactive medication-free or be partial responders (by subjective assessment of referring health care professional) to one psychoactive medication from any of the following classes: antipsychotics, anticonvulsants, mood stabilizers, antidepressants, benzodiazepines, or buspirone. Partial response is defined as some improvement in agitated behavior but persistence of agitated behaviors severe enough to cause patient distress and/or difficulty with caregiving. Although not formally rated, this improvement is equivalent to a CGIC rating of no more than minimal improvement (improvement is noticed by not enough to improve patient function or caregiver's practical management of the patient). - Psychiatric/behavioral: lifetime schizophrenia; current delirium, mania, depression, or uncontrolled persistent distressing psychotic symptoms (hallucinations, delusions), substance abuse, panic disorder, or any behavior which poses an immediate danger to patient or others or which results in the patient being too uncooperative to meet the requirements of study participation.



Primary Contact:

Principal Investigator
Elaine R Peskind, MD
Veterans Affairs Puget Sound Health Care System

Lucy Wang, MD
Phone: 206-277-5089

Backup Contact:


Location Contact:

Seattle, Washington 98108
United States

There is no listed contact information for this specific location.

Site Status: Recruiting

Data Source:

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.